1/10, 4:51 PM (Source: TeleTrader)
more TeleTrader news


Chart for: BAYER AG NA O.N.

Bayer predicts €5B profit from new blood-thinning drug

German pharmaceutical company Bayer AG predicted on Tuesday that its new blood-thinning trial drug, Asundexian, could bring in over €5 billion in annual sales.

The German pharmaceutical company said that the drug, designed to prevent strokes and thrombosis, has a peak sales potential of more than €12 billion when combined with three other drug hopefuls. Asundexian is aimed to be approved by 2026, according to Stefan Oelrich, head of Bayer's Pharmaceuticals Division.

Bayer announced recently that its sales for the third quarter of fiscal 2022 came in at €11.3 billion, jumping 15.3% on an annual basis. Bayer's stock reacted positively to today's news gaining 4.74% at 4:42 pm CET.

Baha Breaking News (BBN) / KB